HLB Therapeutics Co.,Ltd.

KOSDAQ:A115450 Stock Report

Market Cap: ₩950.2b

HLB TherapeuticsLtd Past Earnings Performance

Past criteria checks 0/6

HLB TherapeuticsLtd has been growing earnings at an average annual rate of 6.7%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 0.1% per year.

Key information

6.7%

Earnings growth rate

14.6%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate0.1%
Return on equity-17.0%
Net Margin-50.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 36% Share Price Surge Not Quite Adding Up

Jan 03
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 36% Share Price Surge Not Quite Adding Up

HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Shares Climb 36% But Its Business Is Yet to Catch Up

Nov 18
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Shares Climb 36% But Its Business Is Yet to Catch Up

What HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 36% Share Price Gain Is Not Telling You

Nov 18
What HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 36% Share Price Gain Is Not Telling You

Is HLB TherapeuticsLtd (KOSDAQ:115450) A Risky Investment?

Sep 25
Is HLB TherapeuticsLtd (KOSDAQ:115450) A Risky Investment?

What HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 27% Share Price Gain Is Not Telling You

Jul 22
What HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 27% Share Price Gain Is Not Telling You

HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Popularity With Investors Under Threat As Stock Sinks 26%

Jun 03
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Popularity With Investors Under Threat As Stock Sinks 26%

HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 38% Share Price Surge Not Quite Adding Up

Apr 11
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 38% Share Price Surge Not Quite Adding Up

There's Reason For Concern Over HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Massive 50% Price Jump

Feb 26
There's Reason For Concern Over HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Massive 50% Price Jump

Does G-treeBNT (KOSDAQ:115450) Have A Healthy Balance Sheet?

Mar 19
Does G-treeBNT (KOSDAQ:115450) Have A Healthy Balance Sheet?

Did Business Growth Power G-treeBNT's (KOSDAQ:115450) Share Price Gain of 134%?

Dec 21
Did Business Growth Power G-treeBNT's (KOSDAQ:115450) Share Price Gain of 134%?

Revenue & Expenses Breakdown

How HLB TherapeuticsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A115450 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2455,298-27,90516,8580
30 Jun 2460,298-26,46317,5300
31 Mar 2457,155-1,20317,0990
31 Dec 2353,749-1,99215,1750
30 Sep 2344,190-4,05115,758-15
30 Jun 2349,527-5,96118,6100
31 Mar 2341,008-9,31515,0300
31 Dec 2242,403-10,82315,1300
30 Sep 2247,398-11,47114,68915
30 Jun 2241,579-10,71010,4610
31 Mar 2247,116-16,90514,4070
31 Dec 2143,586-17,19715,3400
30 Sep 2146,554-16,83315,9020
30 Jun 2139,427-18,28716,1740
31 Mar 2140,881-18,46917,7940
31 Dec 2042,930-16,90217,0250
30 Sep 2047,746-20,61820,8120
30 Jun 2057,262-18,76419,9030
31 Mar 2059,171-14,85716,6130
31 Dec 1958,966-15,97516,4480
30 Sep 1953,593-9,63712,0020
30 Jun 1953,5831,94010,5880
31 Mar 1948,2333,6539,5240
31 Dec 1843,5854,5198,13811
30 Sep 1833,3656,7065,118300
30 Jun 1817,023-4,0105,403741
31 Mar 1817,407-3,9635,1061,141
31 Dec 1717,152-4,8165,4701,130
30 Sep 1717,350-5,7586,411840
30 Jun 1717,055-5,8866,391400
31 Mar 1717,083-5,9956,8820
31 Dec 1617,710-5,2006,9130
30 Sep 1617,764-4,0725,929403
30 Jun 1617,796-3,8255,897403
31 Mar 1617,640-3,7895,407403
31 Dec 1516,782-4,3015,609403
30 Sep 1516,406-4,3815,380801
30 Jun 1516,637-3,7754,941801
31 Mar 1516,808-3,0094,904801
31 Dec 1417,618-1,3464,200801
30 Sep 141,740-3,7253,3970
30 Jun 1412,314-4,5534,3760
31 Mar 148,337-4,5363,7010

Quality Earnings: A115450 is currently unprofitable.

Growing Profit Margin: A115450 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A115450 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.7% per year.

Accelerating Growth: Unable to compare A115450's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A115450 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A115450 has a negative Return on Equity (-17.01%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 10:40
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HLB Therapeutics Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae KimDAOL Investment & Securities Co., Ltd.
Seung Kyu JungKiwoom Securities Co., Ltd.